{"id":"W4404353984","doi":"10.1016/s0140-6736(24)01774-4","title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Oxaliplatin; Rituximab; Medicine; Refractory (planetary science); Gemcitabine; Open label; Diffuse large B-cell lymphoma; Internal medicine; Oncology; Lymphoma; Phases of clinical research; Clinical trial; Chemotherapy; Cancer; Colorectal cancer; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007887674,0.0004367411,0.001303065,0.00005639756,0.0002802608,0.000347537,0.000393295,0.0001788867,0.0001280439],"category_scores_gemma":[0.000419505,0.0002510931,0.0001812815,0.0002938404,0.0001161579,0.0002157348,0.0002498391,0.0001347886,0.0001013914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006574246,"about_ca_system_score_gemma":0.000513159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001343539,"about_ca_topic_score_gemma":0.0000971487,"domain_scores_codex":[0.9975658,0.0001464057,0.000541984,0.0006688992,0.0003757743,0.0007011396],"domain_scores_gemma":[0.997485,0.001203637,0.0001463124,0.0008396428,0.00007359849,0.0002517721],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8569392,0.01530435,0.00004606912,0.0003812446,0.0007625219,0.0005645595,0.0003857424,2.609137e-7,0.0001514178,0.002088091,0.09432904,0.02904753],"study_design_scores_gemma":[0.8393526,0.00457646,0.0001132344,0.0002208216,0.001112106,0.00006839375,0.0001315161,0.002035184,0.0002323887,0.0002268004,0.1516638,0.0002666423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9717225,0.007314092,0.0001312148,0.006769026,0.001771088,0.006086374,0.00170225,0.0002467944,0.004256666],"genre_scores_gemma":[0.9894,0.001285707,0.00178735,0.001290306,0.002076218,0.001201758,0.0003761396,0.00007465721,0.002507806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0573348,"threshold_uncertainty_score":0.9999942,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07879406084213593,"score_gpt":0.3781979043351438,"score_spread":0.2994038434930079,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}